Bolt Biotherapeutics (6LP0) Ownership - Who Owns Bolt Biotherapeutics?
Bolt Biotherapeutics (6LP0) Ownership Overview
- 7.62% Insiders
- 3.89% Mutual Funds
- 1.97% Other Institutional Investors
- 0.37% ETFs
- 86.15% Public Companies and Individual Investors
The ownership structure of Bolt Biotherapeutics (DE:6LP0) stock is a mix of institutional, retail, and individual investors. Approximately 6.23% of the company’s stock is owned by Institutional Investors, 7.62% is owned by Insiders, and 86.15% is owned by Public Companies and Individual Investors.
The ownership structure of Bolt Biotherapeutics (DE:6LP0) stock is a mix of institutional, retail, and individual investors. Approximately 6.23% of the company’s stock is owned by Institutional Investors, 7.62% is owned by Insiders, and 86.15% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Sep 20, 2026 | William P. Quinn | $58,282 | |
| Sep 20, 2026 | Sarah Nemec | $26,019 | |
| Sep 20, 2026 | Grant Yonehiro | $43,716 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Sheila Gujrathi | 85,821 | Insider | 4.46% | 496,474 |
| Fidelity Commonwealth Trust Ii | 50,695 | Institution | 2.63% | 293,271 |
| William P. Quinn | 25,384 | Insider | 1.32% | 146,846 |
| Grant Yonehiro | 17,269 | Insider | 0.90% | 99,901 |
| Sarah Nemec | 17,082 | Insider | 0.89% | 98,819 |
| Fidelity Concord Street Trust | 14,513 | Institution | 0.75% | 83,958 |
| BlackRock, Inc. | 9,711 | Institution | 0.50% | 56,178 |
| Vanguard | 7,060 | Institution | 0.37% | 40,842 |
| Vanguard Index Funds | 7,060 | Institution | 0.37% | 40,842 |
| Victory Portfolios Iii | 2,700 | Institution | 0.14% | 15,620 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Fidelity Commonwealth Trust Ii | 50,695 | Institution | 2.63% | 293,271 |
| Fidelity Concord Street Trust | 14,513 | Institution | 0.75% | 83,958 |
| Vanguard Index Funds | 7,060 | Institution | 0.37% | 40,842 |
| Victory Portfolios Iii | 2,700 | Institution | 0.14% | 15,620 |
FAQ
Who Owns Bolt Biotherapeutics (DE:6LP0)?
According to the latest TipRanks data, approximately 6.23% of the company's stock is held by institutional investors, 7.62% is held by insiders, and 86.15% is held by public companies and individual investors.
What percentage of Bolt Biotherapeutics (DE:6LP0) stock is held by institutional investors?
According to the latest TipRanks data, approximately 6.23% of Bolt Biotherapeutics (DE:6LP0) stock is held by institutional investors: 3.89% by mutual funds, 0.37% by ETFs and 1.97% by other institutional investors.
What percentage of Bolt Biotherapeutics (DE:6LP0) stock is held by retail investors?
According to the latest TipRanks data, approximately 86.15% of Bolt Biotherapeutics (DE:6LP0) stock is held by public companies and individual investors.
Who owns the most shares of Bolt Biotherapeutics (DE:6LP0)?
Sheila Gujrathi owns the most shares of Bolt Biotherapeutics (DE:6LP0).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
